GLP-1 & Metabolic
Metabolic health, appetite regulation, and modern weight management.
58 articles in GLP-1 & Metabolic
Reading a GLP-1 Headline Without Getting Misled
A practical guide to the difference between a trial result and a press release.
Read →GLP-1s and Bone Density: An Open Question
Rapid weight loss can affect bone. What the limited data shows and why it's worth watching.
Read →Semaglutide and Cardiovascular Risk: What SELECT Actually Showed
The SELECT trial found a 20% reduction in major cardiac events — independent of weight loss. Here's what that means, and what it doesn't.
Read →The Side-Effect Curve: Why Most Quit in Month One
Discontinuation clusters early. Understanding why is the key to staying on track.
Read →GLP-1s for Maintenance vs Active Loss
Using these drugs to hold weight is different from using them to lose it. The evidence on each.
Read →What 'Food Noise' Tells Us About Obesity Biology
A patient-coined phrase that's reframing how scientists think about appetite.
Read →GLP-1s and Mental Health: Untangling the Signals
Mixed reports, real questions. A careful read of an emotionally charged topic.
Read →Can Training Offset GLP-1 Muscle Loss?
Resistance training is the obvious lever. What the evidence says it can and can't protect.
Read →Cardiometabolic Risk: Where GLP-1s Fit
Placing these drugs in the broader picture of heart and metabolic disease prevention.
Read →Tolerance to GLP-1s: Does It Happen?
Whether the body adapts and the effect fades — what the long-term data suggests.
Read →GLP-1s and Insurance Coverage in 2026
Access still hinges on coverage. The current state of a fast-moving landscape.
Read →The History of Incretin Research, Briefly
From a curious gut observation to the biggest drug class in a generation.
Read →GLP-1s and Appetite Hormones: Leptin and Ghrelin
How GLP-1 drugs interact with the body's other hunger signals.
Read →How GLP-1s Slow Gastric Emptying
The mechanism behind both the fullness and the nausea, explained simply.
Read →GLP-1s and Eating Disorders: A Cautious Look
An area where the appetite effects demand particular care. What's known and what isn't.
Read →Why GLP-1 Trials Use Different Endpoints
Weight, A1c, cardiovascular events — what a trial measures shapes what its result means.
Read →GLP-1s in Adolescents: The Evidence and the Debate
Pediatric use raises real questions. What the trials show and what clinicians weigh.
Read →The Durability Question: GLP-1s as Chronic Therapy
These look more like blood-pressure drugs than a course of antibiotics. Why that framing matters.
Read →Amylin and the Next Wave: CagriSema, Explained
Pairing an amylin analog with a GLP-1 is the next combination strategy. The early data, in context.
Read →GLP-1s and Blood Pressure: What the Trials Found
A modest but consistent effect that adds to the cardiometabolic case.
Read →GLP-1s and Cholesterol: Secondary Metabolic Effects
Weight isn't the only marker that moves. What the lipid data shows.
Read →Survodutide and the GLP-1/Glucagon Approach
Another dual-agonist strategy with a different second target. What it's being tested for.
Read →GLP-1 Shortages: What Drove Them and What's Next
Demand outran supply for years. What caused it and how the picture is changing.
Read →GLP-1s and the Gut Microbiome
An early but real research thread on how these drugs and your microbes interact.
Read →Generic GLP-1s: When Will Prices Fall?
Patents, manufacturing, and supply — the forces that will eventually reshape access.
Read →Protein Intake on a GLP-1: Why It Matters More
When appetite drops, protein becomes the variable that protects muscle. The evidence and the targets.
Read →GLP-1s and Cognitive Health: Early Signals
From appetite to memory — why researchers are studying GLP-1s in the brain, cautiously.
Read →Tirzepatide for Heart Failure: The SUMMIT Trial
A GLP-1/GIP drug moved a heart-failure endpoint. What that adds to the cardiometabolic picture.
Read →GLP-1s and 'Food Noise': The Science of Reduced Cravings
The most striking patient-reported effect may say something deep about the biology of appetite.
Read →Will GLP-1s Work for You? Predicting Response
Response varies widely. What the research says about who loses the most — and why.
Read →GLP-1s and Exercise: A Better-Together Story
Training doesn't just add to GLP-1 results — it changes their composition. Here's how.
Read →GLP-1s in Type 2 Diabetes vs Obesity: Different Goals
Same drug class, different endpoints and expectations depending on why it's prescribed.
Read →Rebound Weight After GLP-1s: What Studies Show
Stopping usually means regaining. The numbers, the mechanisms, and what it means for treatment.
Read →The Incretin Effect, Explained
Why food triggers more insulin than glucose alone — the biology GLP-1 drugs exploit.
Read →GLP-1s and Pancreatitis: What the Data Says
A long-standing concern examined against the accumulated trial and real-world evidence.
Read →GLP-1s and Gastroparesis: Weighing the Risk
Slowed stomach emptying is the mechanism and the side effect. Where the concern is real.
Read →GLP-1 Dosing and Titration: Why Slow Wins
The escalation schedule isn't bureaucracy — it's how you trade side effects for tolerability.
Read →GLP-1s and Thyroid Cancer: Reading the Black-Box Warning
Where the warning comes from, what the rodent data showed, and what human evidence suggests.
Read →GLP-1s and Kidney Outcomes: The FLOW Trial, Explained
A kidney-outcomes trial added another organ to the GLP-1 story. What it found and didn't.
Read →How GLP-1, GIP, and Glucagon Differ
Three hormones, three roles. Understanding them is the key to understanding the newest drugs.
Read →GLP-1s and PCOS: What the Research Shows
Insulin resistance links PCOS and GLP-1 biology. The evidence is promising but still maturing.
Read →GLP-1 Receptor Agonists in the Brain: Appetite and Beyond
These drugs act centrally, not just in the gut. What that means for appetite, reward, and side effects.
Read →GLP-1s and Alcohol Use: An Emerging Signal
Anecdotes and early data hint at reduced drinking. A measured look at a genuinely interesting signal.
Read →GLP-1s and Cardiovascular Outcomes Beyond SELECT
SELECT was the landmark, but the cardiovascular story is broader. What the wider evidence shows.
Read →Compounded Semaglutide: The Risks and Realities
Cheaper, less regulated, and riskier. What to understand about the compounded market.
Read →GLP-1s and Fatty Liver Disease (MASH): The Evidence
Metabolic liver disease is an active GLP-1 frontier. Where the trials currently stand.
Read →Microdosing GLP-1s: Evidence or Anecdote?
Sub-therapeutic dosing is popular online. The controlled evidence behind it is essentially nonexistent.
Read →GLP-1s for Sleep Apnea: Reading the SURMOUNT-OSA Data
A GLP-1 trial moved an apnea endpoint. What that signals about metabolic disease and breathing.
Read →GLP-1 Side Effects: What the Trials Report
Nausea leads the list, but the full picture matters. What the controlled data actually documents.
Read →The GLP-1 Weight-Loss Plateau, Explained
Why the scale stops moving, what's happening physiologically, and what the data says to expect.
Read →GLP-1s and Muscle Loss: Protecting Lean Mass
Rapid weight loss takes muscle with it. What DEXA studies show and how training and protein respond.
Read →Managing GLP-1 Nausea: What the Evidence Suggests
Most GLP-1 nausea is dose- and titration-related. Here's what the research says helps.
Read →What Happens When You Stop a GLP-1?
The regain question is the most important one — and the trials give a fairly clear answer.
Read →Retatrutide: The Triple Agonist on the Horizon
Early trials of the GIP/GLP-1/glucagon triple agonist show the largest losses yet — with the usual caveats.
Read →Oral Semaglutide: Does the Pill Match the Injection?
An oral GLP-1 removes the needle — but absorption, dosing, and effect size all come with asterisks.
Read →Tirzepatide: How the Dual Agonist Changed the Field
Hitting GIP and GLP-1 at once produced weight-loss numbers that reset expectations. Here's why it works.
Read →Semaglutide vs Tirzepatide: Comparing the Heavyweights
Head-to-head data now exists. What it shows about efficacy, tolerability, and trade-offs.
Read →Liraglutide: The GLP-1 That Started It All
Before semaglutide, there was liraglutide. What the first widely used GLP-1 taught the field.
Read →